Does the media prefer IART or CV?

In the previous week, Integra LifeSciences had 21 more articles in the media than CapsoVision. MarketBeat recorded 28 mentions for Integra LifeSciences and 7 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.47 beat Integra LifeSciences' score of 0.05 indicating that CapsoVision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integra LifeSciences 1 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Neutral CapsoVision 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, CV or BVS?

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CapsoVision $13.55M 22.79 -$25.32M -$0.47 N/A Bioventus $581.85M 1.90 $22.73M $0.77 17.05

Is CV or BVS more profitable?

Bioventus has a net margin of 9.36% compared to CapsoVision's net margin of -214.74%. Bioventus' return on equity of 28.08% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -214.74% -177.85% -135.07% Bioventus 9.36% 28.08% 9.82%

Does the media favor CV or BVS?

In the previous week, CapsoVision had 4 more articles in the media than Bioventus. MarketBeat recorded 7 mentions for CapsoVision and 3 mentions for Bioventus. CapsoVision's average media sentiment score of 0.47 beat Bioventus' score of 0.34 indicating that CapsoVision is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, AORT or CV?

Artivion has higher revenue and earnings than CapsoVision. Artivion is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artivion $441.33M 2.46 $9.77M -$0.07 N/A CapsoVision $13.55M 22.79 -$25.32M -$0.47 N/A

Is AORT or CV more profitable?

Artivion has a net margin of -0.67% compared to CapsoVision's net margin of -214.74%. Artivion's return on equity of 6.07% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets Artivion -0.67% 6.07% 2.93% CapsoVision -214.74% -177.85% -135.07%

Does the media prefer AORT or CV?

In the previous week, CapsoVision had 6 more articles in the media than Artivion. MarketBeat recorded 7 mentions for CapsoVision and 1 mentions for Artivion. CapsoVision's average media sentiment score of 0.47 beat Artivion's score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CapsoVision 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, IRMD or CV?

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.03 $22.48M $1.79 47.71 CapsoVision $13.55M 22.79 -$25.32M -$0.47 N/A

Is IRMD or CV more profitable?

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -214.74%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.45% 20.36% CapsoVision -214.74% -177.85% -135.07%

Does the media refer more to IRMD or CV?

In the previous week, CapsoVision had 4 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for CapsoVision and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat CapsoVision's score of 0.47 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CapsoVision 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CapsoVision (CV) Competitors

$6.59 +0.42 (+6.81%)

Closing price 04:00 PM Eastern

Extended Trading

$6.67 +0.08 (+1.18%)

As of 05:41 PM Eastern

Compare

CV vs. DRTS, IART, BVS, AORT, and IRMD

Should you buy CapsoVision stock or one of its competitors? CapsoVision's main competitors and comparable companies include Alpha Tau Medical (DRTS), Integra LifeSciences (IART), Bioventus (BVS), Artivion (AORT), and iRadimed (IRMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does CapsoVision compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

CapsoVision has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A
CapsoVision	$13.55M	22.79	-$25.32M	-$0.47	N/A

Alpha Tau Medical has a net margin of 0.00% compared to CapsoVision's net margin of -214.74%. Alpha Tau Medical's return on equity of -138.12% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-138.12%	-81.68%
CapsoVision	-214.74%	-177.85%	-135.07%

2.7% of Alpha Tau Medical shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by insiders. Comparatively, 2.3% of CapsoVision shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, CapsoVision had 7 more articles in the media than Alpha Tau Medical. MarketBeat recorded 7 mentions for CapsoVision and 0 mentions for Alpha Tau Medical. CapsoVision's average media sentiment score of 0.47 beat Alpha Tau Medical's score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
Alpha Tau Medical	Neutral
CapsoVision	Neutral

Alpha Tau Medical has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, CapsoVision has a beta of -2.45, indicating that its stock price is 345% less volatile than the broader market.

Alpha Tau Medical currently has a consensus price target of $15.40, indicating a potential upside of 4.27%. CapsoVision has a consensus price target of $9.50, indicating a potential upside of 53.97%. Given CapsoVision's higher possible upside, analysts clearly believe CapsoVision is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Alpha Tau Medical beats CapsoVision on 8 of the 15 factors compared between the two stocks.

How does CapsoVision compare to Integra LifeSciences?

Integra LifeSciences (NASDAQ:IART) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Integra LifeSciences has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, CapsoVision has a beta of -2.45, indicating that its stock price is 345% less volatile than the broader market.

Integra LifeSciences currently has a consensus price target of $18.43, indicating a potential upside of 45.34%. CapsoVision has a consensus price target of $9.50, indicating a potential upside of 53.97%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts plainly believe CapsoVision is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

CapsoVision has lower revenue, but higher earnings than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.64B	0.60	-$516.47M	-$0.09	N/A
CapsoVision	$13.55M	22.79	-$25.32M	-$0.47	N/A

Integra LifeSciences has a net margin of -0.44% compared to CapsoVision's net margin of -214.74%. Integra LifeSciences' return on equity of 18.30% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-0.44%	18.30%	5.30%
CapsoVision	-214.74%	-177.85%	-135.07%

In the previous week, Integra LifeSciences had 21 more articles in the media than CapsoVision. MarketBeat recorded 28 mentions for Integra LifeSciences and 7 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.47 beat Integra LifeSciences' score of 0.05 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	1 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Neutral
CapsoVision	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.8% of Integra LifeSciences shares are held by institutional investors. 3.8% of Integra LifeSciences shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Integra LifeSciences beats CapsoVision on 9 of the 16 factors compared between the two stocks.

How does CapsoVision compare to Bioventus?

CapsoVision (NASDAQ:CV) and Bioventus (NASDAQ:BVS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, CapsoVision had 4 more articles in the media than Bioventus. MarketBeat recorded 7 mentions for CapsoVision and 3 mentions for Bioventus. CapsoVision's average media sentiment score of 0.47 beat Bioventus' score of 0.34 indicating that CapsoVision is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CapsoVision presently has a consensus target price of $9.50, indicating a potential upside of 53.97%. Bioventus has a consensus target price of $16.80, indicating a potential upside of 27.95%. Given CapsoVision's higher probable upside, equities analysts clearly believe CapsoVision is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bioventus	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Bioventus has a net margin of 9.36% compared to CapsoVision's net margin of -214.74%. Bioventus' return on equity of 28.08% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Bioventus	9.36%	28.08%	9.82%

62.9% of Bioventus shares are held by institutional investors. 2.3% of CapsoVision shares are held by insiders. Comparatively, 33.5% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CapsoVision has a beta of -2.45, meaning that its share price is 345% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Bioventus has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	22.79	-$25.32M	-$0.47	N/A
Bioventus	$581.85M	1.90	$22.73M	$0.77	17.05

Summary

Bioventus beats CapsoVision on 12 of the 16 factors compared between the two stocks.

How does CapsoVision compare to Artivion?

Artivion (NYSE:AORT) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

86.4% of Artivion shares are owned by institutional investors. 6.3% of Artivion shares are owned by insiders. Comparatively, 2.3% of CapsoVision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, CapsoVision had 6 more articles in the media than Artivion. MarketBeat recorded 7 mentions for CapsoVision and 1 mentions for Artivion. CapsoVision's average media sentiment score of 0.47 beat Artivion's score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artivion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CapsoVision	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artivion has higher revenue and earnings than CapsoVision. Artivion is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artivion	$441.33M	2.46	$9.77M	-$0.07	N/A
CapsoVision	$13.55M	22.79	-$25.32M	-$0.47	N/A

Artivion currently has a consensus price target of $44.83, indicating a potential upside of 101.50%. CapsoVision has a consensus price target of $9.50, indicating a potential upside of 53.97%. Given Artivion's stronger consensus rating and higher probable upside, research analysts clearly believe Artivion is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artivion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Artivion has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, CapsoVision has a beta of -2.45, suggesting that its share price is 345% less volatile than the broader market.

Artivion has a net margin of -0.67% compared to CapsoVision's net margin of -214.74%. Artivion's return on equity of 6.07% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artivion	-0.67%	6.07%	2.93%
CapsoVision	-214.74%	-177.85%	-135.07%

Summary

Artivion beats CapsoVision on 12 of the 16 factors compared between the two stocks.

How does CapsoVision compare to iRadimed?

iRadimed (NASDAQ:IRMD) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

iRadimed has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.03	$22.48M	$1.79	47.71
CapsoVision	$13.55M	22.79	-$25.32M	-$0.47	N/A

iRadimed has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, CapsoVision has a beta of -2.45, suggesting that its share price is 345% less volatile than the broader market.

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 40.52%. CapsoVision has a consensus price target of $9.50, indicating a potential upside of 53.97%. Given CapsoVision's higher possible upside, analysts plainly believe CapsoVision is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, CapsoVision had 4 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for CapsoVision and 3 mentions for iRadimed. iRadimed's average media sentiment score of 1.04 beat CapsoVision's score of 0.47 indicating that iRadimed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CapsoVision	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

92.3% of iRadimed shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 2.3% of CapsoVision shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

iRadimed has a net margin of 26.70% compared to CapsoVision's net margin of -214.74%. iRadimed's return on equity of 23.45% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.45%	20.36%
CapsoVision	-214.74%	-177.85%	-135.07%

Summary

iRadimed beats CapsoVision on 13 of the 16 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CV vs. The Competition

Export

Metric	CapsoVision	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$329.83M	$5.52B	$7.17B	$13.38B
Dividend Yield	N/A	1.79%	2.53%	17.32%
P/E Ratio	-14.02	25.76	274.64	26.20
Price / Sales	24.34	42.33	608.14	90.60
Price / Cash	N/A	32.73	27.22	34.70
Price / Book	23.54	6.04	11.26	6.40
Net Income	-$25.32M	$146.97M	$3.49B	$381.07M
7 Day Performance	-4.77%	-0.99%	-1.68%	-0.65%
1 Month Performance	10.02%	-4.32%	-5.97%	-4.50%
1 Year Performance	37.58%	2.44%	8.10%	1.82%

CapsoVision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CV CapsoVision	3.3685 of 5 stars	$6.59 +6.8%	$9.50 +44.2%	+28.8%	$329.83M	$13.55M	N/A	99	Positive News
DRTS Alpha Tau Medical	1.1121 of 5 stars	$15.04 +3.4%	$15.40 +2.4%	+242.7%	$1.31B	N/A	N/A	121	News Coverage
IART Integra LifeSciences	3.8229 of 5 stars	$16.27 +0.9%	$18.86 +15.9%	-14.3%	$1.25B	$1.64B	N/A	4,427	Trending News Analyst Downgrade
BVS Bioventus	3.6024 of 5 stars	$14.02 +1.5%	$16.80 +19.8%	+87.0%	$1.16B	$581.85M	18.21	950
AORT Artivion	2.8804 of 5 stars	$23.02 +1.7%	$44.83 +94.8%	-45.8%	$1.10B	$441.33M	N/A	1,800

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CV) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CapsoVision (CV) Competitors

CV vs. DRTS, IART, BVS, AORT, and IRMD

How does CapsoVision compare to Alpha Tau Medical?

Summary

How does CapsoVision compare to Integra LifeSciences?

Summary

How does CapsoVision compare to Bioventus?

Summary

How does CapsoVision compare to Artivion?

Summary

How does CapsoVision compare to iRadimed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CapsoVision (CV) Competitors

CV vs. DRTS, IART, BVS, AORT, and IRMD

How does CapsoVision compare to Alpha Tau Medical?

Which has stronger earnings & valuation, DRTS or CV?

Is DRTS or CV more profitable?

Do institutionals and insiders believe in DRTS or CV?

Does the media favor DRTS or CV?

Which has more risk and volatility, DRTS or CV?

Do analysts rate DRTS or CV?

Summary

How does CapsoVision compare to Integra LifeSciences?

Which has more risk and volatility, IART or CV?

Do analysts rate IART or CV?

Which has better valuation & earnings, IART or CV?

Is IART or CV more profitable?

Does the media prefer IART or CV?

Do institutionals and insiders hold more shares of IART or CV?

Summary

How does CapsoVision compare to Bioventus?

Does the media favor CV or BVS?

Do analysts rate CV or BVS?

Is CV or BVS more profitable?

Do institutionals & insiders hold more shares of CV or BVS?

Which has more volatility & risk, CV or BVS?

Which has preferable valuation & earnings, CV or BVS?

Summary

How does CapsoVision compare to Artivion?

Do institutionals & insiders believe in AORT or CV?

Does the media prefer AORT or CV?

Which has stronger earnings and valuation, AORT or CV?

Do analysts recommend AORT or CV?

Which has more risk & volatility, AORT or CV?

Is AORT or CV more profitable?

Summary

How does CapsoVision compare to iRadimed?

Which has better earnings and valuation, IRMD or CV?

Which has more risk & volatility, IRMD or CV?

Do analysts recommend IRMD or CV?

Does the media refer more to IRMD or CV?

Do insiders & institutionals believe in IRMD or CV?

Is IRMD or CV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CV vs. The Competition

CapsoVision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools